Ganymed Pharmaceuticals’ IMAB362 for the treatment of pancreatic cancer has been granted orphan drug designation by the FDA and EMA. IMAB362 is a monoclonal antibody currently in Phase IIb development for gastroesophageal cancer.   IMAB362 selectively binds to the protein CLDN18.2, which is expressed in approximately 60% of primary and metastatic pancreatic cancers and approximately 80% of gastroesophageal cancers, as well as other solid tumors. The drug represents an advantage in that CLDN18.2 ...